MX2023003993A - Tratamiento de trastornos bipolares y psicosis con clorhidrato de dexmedetomidina. - Google Patents

Tratamiento de trastornos bipolares y psicosis con clorhidrato de dexmedetomidina.

Info

Publication number
MX2023003993A
MX2023003993A MX2023003993A MX2023003993A MX2023003993A MX 2023003993 A MX2023003993 A MX 2023003993A MX 2023003993 A MX2023003993 A MX 2023003993A MX 2023003993 A MX2023003993 A MX 2023003993A MX 2023003993 A MX2023003993 A MX 2023003993A
Authority
MX
Mexico
Prior art keywords
psychosis
bipolar disorders
treatment
dexmedetomidine hydrochloride
methods
Prior art date
Application number
MX2023003993A
Other languages
English (en)
Spanish (es)
Inventor
Vivo Michael De
Frank Yocca
Robert Risinger
Friso Postma
Original Assignee
Bioxcel Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bioxcel Therapeutics Inc filed Critical Bioxcel Therapeutics Inc
Publication of MX2023003993A publication Critical patent/MX2023003993A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4174—Arylalkylimidazoles, e.g. oxymetazolin, naphazoline, miconazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7007—Drug-containing films, membranes or sheets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
MX2023003993A 2020-10-08 2021-10-08 Tratamiento de trastornos bipolares y psicosis con clorhidrato de dexmedetomidina. MX2023003993A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202063089135P 2020-10-08 2020-10-08
PCT/US2021/054171 WO2022076818A1 (en) 2020-10-08 2021-10-08 Treatment of bipolar disorders and psychosis using dexmedetomidine hydrochloride

Publications (1)

Publication Number Publication Date
MX2023003993A true MX2023003993A (es) 2023-05-24

Family

ID=81126063

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2023003993A MX2023003993A (es) 2020-10-08 2021-10-08 Tratamiento de trastornos bipolares y psicosis con clorhidrato de dexmedetomidina.

Country Status (11)

Country Link
US (1) US20240024289A1 (cg-RX-API-DMAC7.html)
EP (1) EP4225305A4 (cg-RX-API-DMAC7.html)
JP (1) JP2023545372A (cg-RX-API-DMAC7.html)
KR (1) KR20230084186A (cg-RX-API-DMAC7.html)
CN (1) CN116615243A (cg-RX-API-DMAC7.html)
AU (1) AU2021356687A1 (cg-RX-API-DMAC7.html)
CA (1) CA3195133A1 (cg-RX-API-DMAC7.html)
IL (1) IL301971A (cg-RX-API-DMAC7.html)
MX (1) MX2023003993A (cg-RX-API-DMAC7.html)
TW (1) TW202228682A (cg-RX-API-DMAC7.html)
WO (1) WO2022076818A1 (cg-RX-API-DMAC7.html)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL267689B2 (en) 2016-12-31 2025-05-01 Bioxcel Therapeutics Inc Use of sublingual dexmedetomidine for the treatment of agitation
IL279713B2 (en) 2018-06-27 2025-01-01 Bioxcel Therapeutics Inc Dexmedetomidine-containing layer compositions and methods for their production
EP3999058A4 (en) 2019-07-19 2023-05-03 Bioxcel Therapeutics, Inc. TREATMENT SCHEMES FOR NON-SEDATING DEXMEDETOMIDIN
EP4297871A4 (en) * 2021-02-26 2025-01-01 BioXcel Therapeutics, Inc. METHODS AND COMPOSITIONS FOR TREATING AGITATION
US11806334B1 (en) 2023-01-12 2023-11-07 Bioxcel Therapeutics, Inc. Non-sedating dexmedetomidine treatment regimens

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8242158B1 (en) * 2012-01-04 2012-08-14 Hospira, Inc. Dexmedetomidine premix formulation
MX368880B (es) * 2012-10-15 2019-10-21 Orion Corp Dexmedetomidina y medetomidina para su uso en el alivio de la aversión al ruido en un animal.
TWI624278B (zh) * 2013-10-07 2018-05-21 帝國製藥美國股份有限公司 使用非鎮靜性右美托咪啶經皮組成物用於治療戒斷症候群的方法及組成物
IL267689B2 (en) * 2016-12-31 2025-05-01 Bioxcel Therapeutics Inc Use of sublingual dexmedetomidine for the treatment of agitation
EP3999058A4 (en) * 2019-07-19 2023-05-03 Bioxcel Therapeutics, Inc. TREATMENT SCHEMES FOR NON-SEDATING DEXMEDETOMIDIN

Also Published As

Publication number Publication date
CN116615243A (zh) 2023-08-18
AU2021356687A1 (en) 2023-06-15
KR20230084186A (ko) 2023-06-12
IL301971A (en) 2023-06-01
TW202228682A (zh) 2022-08-01
US20240024289A1 (en) 2024-01-25
EP4225305A1 (en) 2023-08-16
JP2023545372A (ja) 2023-10-30
EP4225305A4 (en) 2024-10-23
CA3195133A1 (en) 2022-04-14
AU2021356687A9 (en) 2024-10-03
WO2022076818A1 (en) 2022-04-14

Similar Documents

Publication Publication Date Title
MX2021010058A (es) Formulaciones de rapamicina tópicas y su uso en el tratamiento de angiofibromas faciales y otros trastornos de la piel.
MX2020008680A (es) Terapia de combinacion con apilimod y agentes glutamatergicos.
MX2019009227A (es) Métodos para tratar cáncer con inhibidores de hsp90.
MY199903A (en) Combination therapy with controlled-release cnp agonists
MX2021000071A (es) Uso de pridopidina para mejorar la funcion cognitiva y para tratamiento de enfermedad de alzheimer.
MX2024000049A (es) Degradador de tirosina cinasa y mutante de bruton, composicion y aplicacion del mismo.
ZA202304965B (en) Combination therapy for treating cancer
MX2021004207A (es) Uso de reboxetina para el tratamiento de narcolepsia.
MX2025001920A (es) Tratamiento de enfermedades y trastornos asociados a las mitocondrias, incluyendo los sintomas de los mismos usando pridopidina
MY199382A (en) Methods of treating circadian rhythm sleep disorders
MX2021002349A (es) Inhibidores de calicreína en plasmá y usos de los mismos para tratar ataque de angioedema hereditario.
BR112023002458A2 (pt) Métodos de tratamento da gota
MX2024013613A (es) Anticuerpos il-13 para el tratamiento de la dermatitis atopica
MX2023010711A (es) Fenalquilaminas y métodos de preparación y uso de las mismas.
BR112023018944A2 (pt) Composição de terapia gênica e tratamento de cardiomiopatia arritmogênica ventricular direita
MX2024001954A (es) Anticuerpos il-13 para el tratamiento de la dermatitis atopica.
JOP20220168A1 (ar) طرق علاج الطحال
MX2018010223A (es) Terapia combinada para tratamiento de cancer de ovario.
MX2009003532A (es) Tratamiento de hiperbilirrubinemia infantil utilizando bajas dosis de estansoporfina.
MX2023006551A (es) Tratamiento de las convulsiones refractarias.
EP4623999A3 (en) Sotorasib for use in the treatment of cancer
MX2023015097A (es) Tratamiento de sintomas asociados a neoplasias mieloproliferativas.
MX2021011289A (es) Composiciones que comprenden moduladores de isoenzima m2 muscular de piruvato cinasa pkm2 y metodos de tratamiento que usan las mismas.
PH12022551371A1 (en) Macrocycles for use in treating disease
MX2020008881A (es) Métodos de tratamiento contra el cáncer que comprenden inhibidores de chk1.